Evolus, Inc. (NASDAQ:EOLS) Shares Purchased by Schroder Investment Management Group

Schroder Investment Management Group lifted its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 2.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,040,440 shares of the company's stock after purchasing an additional 25,480 shares during the quarter. Schroder Investment Management Group owned about 1.64% of Evolus worth $11,330,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in shares of Evolus by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,210,621 shares of the company's stock valued at $19,616,000 after buying an additional 11,027 shares during the period. Lord Abbett & CO. LLC increased its stake in Evolus by 23.4% during the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company's stock worth $16,126,000 after acquiring an additional 188,685 shares during the last quarter. Rice Hall James & Associates LLC raised its position in Evolus by 4.8% in the fourth quarter. Rice Hall James & Associates LLC now owns 948,281 shares of the company's stock valued at $10,469,000 after purchasing an additional 43,381 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Evolus by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 421,481 shares of the company's stock valued at $4,653,000 after purchasing an additional 2,905 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Evolus by 30.3% during the 3rd quarter. Wellington Management Group LLP now owns 175,039 shares of the company's stock worth $2,836,000 after purchasing an additional 40,715 shares during the period. Hedge funds and other institutional investors own 90.69% of the company's stock.

Evolus Trading Down 8.6 %

NASDAQ EOLS traded down $0.88 during trading on Tuesday, hitting $9.36. The stock had a trading volume of 1,363,416 shares, compared to its average volume of 634,069. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The company has a market capitalization of $595.17 million, a PE ratio of -10.29 and a beta of 0.97. The firm has a 50 day moving average price of $13.20 and a 200 day moving average price of $13.48. Evolus, Inc. has a twelve month low of $9.25 and a twelve month high of $17.82.

Insider Activity

In other news, Director Karah Herdman Parschauer sold 12,888 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total transaction of $167,415.12. Following the sale, the director now owns 32,183 shares of the company's stock, valued at approximately $418,057.17. This represents a 28.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rui Avelar sold 27,904 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.04. Following the completion of the sale, the insider now owns 362,467 shares in the company, valued at approximately $4,806,312.42. The trade was a 7.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 60,575 shares of company stock valued at $794,369. 6.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. HC Wainwright restated a "buy" rating and issued a $27.00 price objective on shares of Evolus in a report on Wednesday, March 5th. Barclays upped their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Evolus in a report on Wednesday, March 5th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.